Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC
- Conditions
- Interventions
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT02037997
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 250
- Registration Number
- NCT02031601
- Locations
- 🇨🇳
Yu Li, Jinan, Shandong, China
A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT02013453
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB
- Conditions
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Xinjiang Medical University
- Target Recruit Count
- 392
- Registration Number
- NCT02001168
- Locations
- 🇨🇳
Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
- Conditions
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 88
- Registration Number
- NCT01982955
- Locations
- 🇨🇳
Jilin University, Changchun, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, China
Nintedanib (BIBF 1120) in Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 545
- Registration Number
- NCT01907100
- Locations
- 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇺🇸Texas Oncology - McAllen, McAllen, Texas, United States
🇺🇸Cancer Care Northwest Centers, PS, Spokane Valley, Washington, United States
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 660
- Registration Number
- NCT01878617
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Texas Children's Cancer Center, Houston, Texas, United States
🇺🇸Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota, United States
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
- Conditions
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 65
- Registration Number
- NCT01868022
- Locations
- 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom
Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT01860040
- Locations
- 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States
Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2023-03-14
- Target Recruit Count
- 632
- Registration Number
- NCT01850303
- Locations
- 🇫🇷
Metz - Belle Isle, Metz, France
🇫🇷Hôpital de Cholet - Pneumologie, Cholet, France
🇫🇷Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.